No Data
Executive Reshuffles: BIIB, USB and WES
Bio-Rad Laboratories Shares Are Trading Higher After Citigroup Maintained a Buy Rating on the Stock and Raised Its Price Target From $400 to $450.
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
Bristol-Myers Squibb Analyst Ratings
'Marc Benioff Is In Talks To Sell Time To Antenna Group; Antenna Group Is In Talks To Acquire Time From Salesforce' - CNBC
Bristol Myers Posts Long-term Phase 3 Data for Schizophrenia Drug Cobenfy